Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3099110 | 0.85 | KCNH2 (0.53) | ADORA3POLBL3MBTL1NPC1RAB9A | |
| SCHEMBL3093848 | 0.85 | NPC1 (0.59) | ADORA3NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL3099398 | 0.84 | ADORA3 (0.65) | ADORA3SMN1; SMN2ALDH1A1ADORA2AADORA2B | |
| SCHEMBL3096895 | 0.82 | ADORA3 (0.62) | ADORA3ALDH1A1ADORA2AADORA2BADORA1 | |
| SCHEMBL3096053 | 0.80 | ADORA3 (0.59) | ADORA3NPC1RAB9ASMN1; SMN2ADORA2A | |
| SCHEMBL3087918 | 0.79 | ADORA3 (0.62) | ADORA3NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3087861 | 0.79 | ADORA3 (0.65) | ADORA3L3MBTL1RAB9AALDH1A1ADORA2A | |
| SCHEMBL3081770 | 0.79 | ADORA3 (0.58) | ADORA3L3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3086772 | 0.78 | ADORA3 (0.60) | ADORA3SMN1; SMN2ALDH1A1ADORA2AADORA2B | |
| SCHEMBL3075260 | 0.77 | ADORA3 (0.70) | ADORA3ALDH1A1ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2164833-B1 | Quinazolinamide derivatives useful for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2015-04-15 | — | — | EP | claimed |
| US-8501754-B2 | Quinazolinamide derivatives | MERCK PATENT GMBH (DE) | 2013-08-06 | — | — | US | claimed |
| US-20100234324-A1 | Quinazolinamide derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234324-A1 | Quinazolinamide derivatives | HSP90AB1, HSP90AA1, HSP90AB2P | ADORA3 3301/4885POLB 3667/4885L3MBTL1 1578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.